Thalmineline is primarily used in the development of pharmaceutical agents targeting central nervous system disorders. It serves as a key intermediate in the synthesis of compounds with potential anxiolytic and sedative properties. Due to its ability to modulate specific neurotransmitter receptors, it is investigated for use in treating anxiety, insomnia, and certain neurodegenerative conditions. Its structural characteristics make it suitable for enhancing blood-brain barrier penetration, improving the efficacy of neuroactive drugs. Additionally, Thalmineline is utilized in preclinical research to study receptor binding and pharmacokinetic behavior of novel therapeutic candidates.